<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Seizures in patients undergoing hemodialysis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Seizures in patients undergoing hemodialysis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Seizures in patients undergoing hemodialysis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Davis, MD, MSTR
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Iheanyichukwu Ogu, MD, FASN, FACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Thomas A Golper, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey S Berns, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 28, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seizures are not uncommon among patients on hemodialysis [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         There are many potential causes of seizures among patients on hemodialysis. In most circumstances, seizure activity occurs during or shortly after the hemodialysis procedure because of the hemodynamic and biochemical changes associated with the process [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         This topic reviews the causes and treatment of seizures in patients on hemodialysis. The management of seizures in patients without kidney failure is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">
          "Overview of the management of epilepsy in adults"
         </a>
         .)
        </p>
        <p>
         A review of other acute complications that may occur during dialysis are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1881.html" rel="external">
          "Acute complications during hemodialysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1600827845">
         <span class="h1">
          NEW-ONSET SEIZURE
         </span>
        </p>
        <p class="headingAnchor" id="H1520125319">
         <span class="h2">
          Causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation of a new-onset seizure is similar to that of patients who are not on dialysis. The following causes are due to either end-stage kidney disease (ESKD) or treatment with hemodialysis: uremic encephalopathy, dialysis dysequilibrium syndrome (DDS), intradialytic hemodynamic instability, aluminum-associated dialysis dementia, air embolism, hypoglycemia, hypocalcemia, and hyponatremia.
        </p>
        <p>
         Other causes of seizures among patients on hemodialysis are similar to the general population but may be more common among patients on hemodialysis. Cerebrovascular disease (infarction, cerebral emboli [separate from infarction because dialysis vascular access can lead to infections and septic emboli] [
         <a href="#rid2">
          2
         </a>
         ], hemorrhage and subdural hematoma) is of particular concern in the hemodialysis population. (See
         <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">
          "Evaluation and management of the first seizure in adults", section on 'Causes of seizures'
         </a>
         .)
        </p>
        <p>
         Compared with patients not on dialysis, patients on hemodialysis are more vulnerable to drug-induced seizures with certain drugs such as carbapenem and
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         because of their markedly decreased clearance.
        </p>
        <p>
         The following paragraphs discuss the more common causes of seizures that are specific for the dialysis population. Some are independent of dialysis, whereas others are a direct complication of the procedure.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Uremic encephalopathy
         </strong>
         – Central nervous system (CNS) dysfunction is observed among patients with severe, untreated uremia but generally not among patients undergoing maintenance hemodialysis unless patients miss multiple treatments. Symptoms range from irritability and restlessness to seizures, coma, and death. Seizures are most often generalized and occur prior to dialysis, often provoking initiation of emergent dialysis. CNS dysfunction abates within days to weeks after the initiation of adequate kidney replacement therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dialysis disequilibrium syndrome
         </strong>
         – DDS may be observed among severely uremic patients who undergo hemodialysis for the first time but generally does not occur among patients who are on maintenance hemodialysis. DDS is characterized by neurologic symptoms of varying severity. Typically, symptoms develop during or immediately after hemodialysis. Early findings include headache, nausea, disorientation, restlessness, blurred vision, and asterixis. More severely affected patients progress to confusion, seizures, coma, and even death. However, DDS also includes many milder signs and symptoms associated with dialysis, such as muscle cramps and dizziness that develop near the end of a dialysis treatment [
         <a href="#rid3">
          3-5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1851.html" rel="external">
          "Dialysis disequilibrium syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         New patients just being started on hemodialysis are at greatest risk, particularly if the blood urea nitrogen (BUN) is markedly elevated (ie, above 170 mg/dL or 60 mmol/L). Other predisposing factors include severe metabolic acidosis, older age, hypocalcemia, and the presence of other CNS disease, such as a preexisting seizure disorder [
         <a href="#rid3">
          3,6-9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Erythropoiesis-stimulating agents
         </strong>
         – A rapid rise in blood pressure due to the administration of erythropoiesis-stimulating agents (ESAs) may result in hypertensive encephalopathy accompanied by seizures [
         <a href="#rid10">
          10
         </a>
         ]. The reported incidence ranges from 2 to 17 percent [
         <a href="#rid10">
          10-12
         </a>
         ]. However, most studies that have reported on seizure incidence are from the early 1990s, when ESA doses and hemoglobin targets were higher than are typically used today. (See
         <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">
          "Treatment of anemia in patients on dialysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Thus, despite cited incidence above, we believe ESA-related seizures are uncommon today. A 2004 meta-analysis showed no increase in the incidence of seizures among patients treated with an ESA compared with those not treated with an ESA; however, studies included both predialysis and dialysis chronic kidney disease (CKD) patients, which may have resulted in an underestimate of incidence among dialysis patients [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is little evidence of increased incidence of seizures in normotensive patients treated with an ESA. (See
         <a class="medical medical_review" href="/z/d/html/1979.html" rel="external">
          "Hypertension associated with erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drugs or toxins ─
         </strong>
         Many medications can cause seizures in the general population  (
         <a class="graphic graphic_table graphicRef106961" href="/z/d/graphic/106961.html" rel="external">
          table 1
         </a>
         ). Patients on hemodialysis are particularly vulnerable to some drugs because of decreased clearance [
         <a href="#rid13">
          13-21
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antibiotics including penicillin, cephalosporins, carbapenem, and
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         , particularly when administered at high doses
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          Meperidine
         </a>
         (due to accumulation of the toxic metabolite, normeperidine)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">
          Metoclopramide
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          Theophylline
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         L-dopa
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          Acyclovir
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intravenous (IV) iodinated contrast material (in high doses)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Star fruit ingestion may also cause severe neurologic dysfunction, including seizures and death in dialysis patients [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dialysis dementia –
         </strong>
         Dialysis dementia is a progressive neurologic disorder that is observed exclusively in patients on dialysis and may manifest as seizures. The cause is exposure to aluminum [
         <a href="#rid24">
          24,25
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/1839.html" rel="external">
          "Aluminum toxicity in chronic kidney disease", section on 'Dementia'
         </a>
         ). The incidence of dialysis dementia has markedly declined because of better water treatment for hemodialysis and the use of non-aluminum-containing phosphate binders for the chronic management of hyperphosphatemia. (See
         <a class="medical medical_review" href="/z/d/html/1891.html" rel="external">
          "Contaminants in water used for hemodialysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3254377093">
         <span class="h2">
          Immediate management of seizures
         </span>
         <span class="headingEndMark">
          —
         </span>
         The emergency treatment of seizures in the patient on dialysis includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stop dialysis and start infusion of IV fluids and oxygen if indicated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Protect the vascular access from harm during the seizure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ensure that the patient is in a safe environment and not at risk from injury (eg, fall risk). If possible, place the patient on their side during the seizure. Do not place anything in the mouth during an active seizure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In most instances, 911 (if hemodialysis is occurring in an outpatient clinic) or a rapid response (if hemodialysis is occurring in the hospital setting) should be called, although most seizures last less than five minutes and spontaneously remit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a patient continues to seize, paramedics or the rapid response team must address airway protection and stabilize the patient. Treatment with IV benzodiazepines is the first-line treatment to stop the ongoing seizure activity. The patient should then be evaluated by a clinician to determine further therapy (eg, with IV antiseizure medications). (See
         <a class="medical medical_review" href="/z/d/html/96933.html" rel="external">
          "Convulsive status epilepticus in adults: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Blood should be sampled for serum levels of glucose, calcium, sodium, magnesium, and other electrolytes, marked abnormalities of which may suggest the underlying cause of the seizure. IV glucose should be administered if hypoglycemia is suspected, along with IV thiamine, particularly in at-risk individuals (eg, history of heavy alcohol use).
        </p>
        <p>
         Further therapies are the same as among the nondialysis population and are discussed elsewhere.
        </p>
        <p class="headingAnchor" id="H3829766300">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the patients have been treated for seizure and dialysis has been stopped, the evaluation of seizure is the same for patients on dialysis as for other patients. Potential causes that should be excluded include uremia itself, subdural hematoma, metabolic disturbances (hyponatremia, hypoglycemia), and drug-induced encephalopathy. In addition, causes of seizure that are not specific for patients on dialysis need to be excluded. (See
         <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">
          "Evaluation and management of the first seizure in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prevention of seizures is targeted to specific causes.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Specific causes
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Uremic encephalopathy
         </strong>
         – Progressive uremic encephalopathy is an absolute indication for the initiation of dialysis. (See
         <a class="medical medical_review" href="/z/d/html/1866.html" rel="external">
          "Indications for initiation of dialysis in chronic kidney disease", section on 'Absolute indications for dialysis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The initiation of dialysis prior to the onset of mental status changes prevents seizures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dialysis disequilibrium syndrome
         </strong>
         – Dialysis disequilibrium syndrome (DDS) is prevented by limiting the reduction in blood urea nitrogen (BUN) per treatment so that there is a gradual reduction that is distributed over several days. This measure prevents seizures but may not prevent mild symptoms such as headache and malaise. (See
         <a class="medical medical_review" href="/z/d/html/1851.html" rel="external">
          "Dialysis disequilibrium syndrome", section on 'Prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Erythropoietin therapy
         </strong>
         – The most important measure to prevent erythropoiesis-stimulating agent (ESA)-induced seizures is to avoid rapid increases in hemoglobin. Hemoglobin target, dosing, and the optimal route of administration are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">
          "Treatment of anemia in patients on dialysis", section on 'Target Hb levels'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dialysis-induced hypotension
         </strong>
         – Prevention of dialysis hypotension involves a variety of maneuvers. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1945.html" rel="external">
          "Intradialytic hypotension in an otherwise stable patient"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          MAINTENANCE ANTISEIZURE THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The indication for antiseizure medications is the same among patients on hemodialysis as in the general population. Long-term therapy with antiseizure medications may not be required if the patient's seizure is due to a reversible cause. (See
         <a class="medical medical_review" href="/z/d/html/2212.html" rel="external">
          "Initial treatment of epilepsy in adults", section on 'When to start antiseizure medication therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2734729709">
         <span class="h2">
          Medication selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients on hemodialysis who are selected for antiseizure medication, the selection of a specific medication depends on multiple variables, and no single antiseizure medication is clearly the most effective or best tolerated  (
         <a class="graphic graphic_table graphicRef109485" href="/z/d/graphic/109485.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2212.html" rel="external">
          "Initial treatment of epilepsy in adults", section on 'Selection of an antiseizure medication'
         </a>
         .)
        </p>
        <p>
         For most patients on hemodialysis, we generally use
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         . Levetiracetam is generally well tolerated, is affordable since generic forms are available, and has few drug-drug interactions. If levetiracetam is used, the preferred dose is 500 to 1000 mg daily, with an extra dose of 250 to 500 mg given at the end of dialysis. (See
         <a class="local">
          'Dosing'
         </a>
         below.)
        </p>
        <p>
         Numerous other agents are effective.
         <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">
          Lacosamide
         </a>
         is an alternative agent that may be used. Lacosamide also has only a few interactions with other agents, including immunosuppressive agents.
        </p>
        <p>
         We generally do not use
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         or
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         among patients on hemodialysis, unless the patient is already stable on one of these agents prior to initiating hemodialysis. Phenytoin and valproic acid have multiple drug-drug interactions and tend to have higher rates of adverse effects [
         <a href="#rid26">
          26-31
         </a>
         ]. (See
         <a class="local">
          'Dosing'
         </a>
         below.)
        </p>
        <p>
         Drug-drug interactions are of particular importance among patients on hemodialysis who are usually on multiple medications (see
         <a class="medical medical_review" href="/z/d/html/2212.html" rel="external">
          "Initial treatment of epilepsy in adults", section on 'Pharmacokinetics'
         </a>
         ). In addition, such patients may eventually receive a kidney transplant and require immunosuppression medications (including glucocorticoids), which have important drug-drug interactions with other agents, such as
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         and
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         (
         <a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1903714429">
         <span class="h2">
          Dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many of the newer and more frequently used antiseizure medications are removed by dialysis. Among patients who are treated with a dialyzable antiseizure medication to prevent recurrent seizures, the dosing regimen must be adjusted to prevent a subtherapeutic plasma level during or after dialysis, which could result in a seizure [
         <a href="#rid32">
          32
         </a>
         ]. The dose of many antiseizure medications require adjustments based upon severity of kidney impairment as detailed for the commonly prescribed antiseizure medications in the table  (
         <a class="graphic graphic_table graphicRef109485" href="/z/d/graphic/109485.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         The following drugs are variably removed by dialysis and must be supplemented in order to maintain therapeutic levels [
         <a href="#rid33">
          33
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          Levetiracetam
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">
          Lacosamide
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          Topiramate
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">
          Zonisamide
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          Lamotrigine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          Phenobarbital
         </a>
         and
         <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">
          primidone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          Gabapentin
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          Carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
        </p>
        <p>
        </p>
        <p>
         Among patients who are on any of these agents, we time the doses such that the medication is given at the end of each dialysis treatment. An alternative approach is to administer an additional dose at the end of each dialysis session.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          Carbamazepine
         </a>
         and
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         are only minimally dialyzed. However, even the small amount that is dialyzed out can result in a decrease in the concentration. The stress of hemodialysis plus the slight decrease in concentration can lower the seizure threshold.
        </p>
        <p>
         We do not use extended-release formulations. An extended-release formulation, given as a supplemental dose after dialysis, will take a longer time to achieve a therapeutic concentration.
        </p>
        <p>
         Some agents, such as
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         and
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         , are not dialyzed and require no postdialysis supplementation [
         <a href="#rid34">
          34,35
         </a>
         ]. Because of this, phenytoin and valproic acid have been commonly used among patients on hemodialysis. However, as noted above, these agents are less commonly used today compared with newer agents. (See
         <a class="local">
          'Maintenance antiseizure therapy'
         </a>
         above.)
        </p>
        <p>
         Among patients who are on
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         or
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         , serum levels need to be carefully interpreted. Phenytoin and valproic acid are highly protein bound, and there is an unpredictable relationship between free and total drug concentrations [
         <a href="#rid26">
          26,27
         </a>
         ]. In patients with hypoalbuminemia (which is very common among those with end-stage kidney disease [ESKD]), there is displacement of the drug from serum proteins with an increase in the volume of distribution.
        </p>
        <p>
         As a result, the patient has the same concentration of free drug (which has the pharmacologic effect) in serum at a lower total blood concentration than does the subject with normal kidney function and without hypoalbuminemia. Free levels should be monitored, if available, rather than total levels.
        </p>
        <p class="headingAnchor" id="H2430918538">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112932.html" rel="external">
          "Society guideline links: Dialysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1391794">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Causes of seizures that are due to either end-stage kidney disease (ESKD) or treatment with hemodialysis include uremic encephalopathy, dialysis dysequilibrium syndrome (DDS), intradialytic hemodynamic instability, aluminum-associated dialysis dementia, air embolism, hypoglycemia, hypocalcemia, and hyponatremia. Other causes of seizures among patients on hemodialysis are similar to the general population but may be more common among patients on hemodialysis. (See
         <a class="local">
          'New-onset seizure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The emergency treatment of seizures in the patient on dialysis includes stopping dialysis, ensuring patient safety, and contacting emergency providers if the seizure is not self-limited or the patient is not known to have a seizure disorder. Blood should be sampled for serum levels of glucose, calcium, sodium, magnesium, and other electrolytes. Intravenous (IV) glucose and thiamine should be administered if hypoglycemia is suspected, along with IV thiamine in at-risk individuals. (See
         <a class="local">
          'Immediate management of seizures'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">
          "Overview of the management of epilepsy in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The indication for antiseizure medications is the same among patients on hemodialysis as in the general population. Long-term therapy with antiseizure medications may not be required if the patient's seizure is due to a reversible cause. (See
         <a class="local">
          'Maintenance antiseizure therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients on hemodialysis who require initiation of an antiseizure medication, we generally use
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         , 500 to 1000 mg daily with an extra dose of 250 to 500 mg given at the end of dialysis  (
         <a class="graphic graphic_table graphicRef109485" href="/z/d/graphic/109485.html" rel="external">
          table 2
         </a>
         ). Levetiracetam is generally well tolerated, is affordable since generic forms are available, and has few drug-drug interactions.
         <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">
          Lacosamide
         </a>
         is a commonly used alternative. We generally do not use
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         or
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         unless the patient is already stable on one of these agents prior to initiating hemodialysis. (See
         <a class="local">
          'Maintenance antiseizure therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Many of the newer antiseizure medications are removed by dialysis. When these drugs are utilized in the hemodialysis patient population, the patient should receive additional medication immediately following hemodialysis to prevent subtherapeutic blood levels. An alternative approach is to time the doses such that the medication is given at the end of each dialysis treatment. (See
         <a class="local">
          'Dosing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H531856351">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Yousri M Barri, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Glenn CM, Astley SJ, Watkins SL. Dialysis-associated seizures in children and adolescents. Pediatr Nephrol 1992; 6:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murali S, Shenoy SV, Prabhu RA, Nagaraju SP. Hypertensive emergency and seizures during haemodialysis. BMJ Case Rep 2021; 14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arieff AI. Dialysis disequilibrium syndrome: current concepts on pathogenesis and prevention. Kidney Int 1994; 45:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rostand SG, Brunzell JD, Cannon RO 3rd, Victor RG. Cardiovascular complications in renal failure. J Am Soc Nephrol 1991; 2:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodrigo F, Shideman J, McHugh R, et al. Osmolality changes during hemodialysis. Natural history, clinical correlations, and influence of dialysate glucose and intravenous mannitol. Ann Intern Med 1977; 86:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zepeda-Orozco D, Quigley R. Dialysis disequilibrium syndrome. Pediatr Nephrol 2012; 27:2205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel N, Dalal P, Panesar M. Dialysis disequilibrium syndrome: a narrative review. Semin Dial 2008; 21:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bagshaw SM, Peets AD, Hameed M, et al. Dialysis Disequilibrium Syndrome: brain death following hemodialysis for metabolic acidosis and acute renal failure--a case report. BMC Nephrol 2004; 5:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall MR, Golper TA. Low-efficiency acute renal replacement therapy: role in acute kidney injury. Semin Dial 2011; 24:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beccari M. Seizures in dialysis patients treated with recombinant erythropoietin. Review of the literature and guidelines for prevention. Int J Artif Organs 1994; 17:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edmunds ME, Walls J, Tucker B, et al. Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1989; 4:1065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strippoli GF, Craig JC, Manno C, Schena FP. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 2004; 15:3154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin CS, Cheng CJ, Chou CH, Lin SH. Piperacillin/tazobactam-induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis. Am J Med Sci 2007; 333:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrara N, Abete P, Giordano M, et al. Neurotoxicity induced by Cefepime in a very old hemodialysis patient. Clin Nephrol 2003; 59:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassan H, Bastani B, Gellens M. Successful treatment of normeperidine neurotoxicity by hemodialysis. Am J Kidney Dis 2000; 35:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davenport A, Goel S, Mackenzie JC. Neurotoxicity of acyclovir in patients with end-stage renal failure treated with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1992; 20:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almond MK, Fan S, Dhillon S, et al. Avoiding acyclovir neurotoxicity in patients with chronic renal failure undergoing haemodialysis. Nephron 1995; 69:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helldén A, Odar-Cederlöf I, Diener P, et al. High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study. Nephrol Dial Transplant 2003; 18:1135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuerer DJ, Brophy PD, Maxvold NJ, et al. High-efficiency dialysis for carbamazepine overdose. J Toxicol Clin Toxicol 2000; 38:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seto AH, Song JC, Guest SS. Ertapenem-associated seizures in a peritoneal dialysis patient. Ann Pharmacother 2005; 39:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muruve DA, Steinman TI. Contrast-induced encephalopathy and seizures in a patient with chronic renal insufficiency. Clin Nephrol 1996; 45:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang JM, Hwang SJ, Kuo HT, et al. Fatal outcome after ingestion of star fruit (Averrhoa carambola) in uremic patients. Am J Kidney Dis 2000; 35:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neto MM, da Costa JA, Garcia-Cairasco N, et al. Intoxication by star fruit (Averrhoa carambola) in 32 uraemic patients: treatment and outcome. Nephrol Dial Transplant 2003; 18:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 1976; 294:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahoney CA, Arieff AI. Uremic encephalopathies: clinical, biochemical, and experimental features. Am J Kidney Dis 1982; 2:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reidenberg MM. The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function. Am J Med 1977; 62:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Israni RK, Kasbekar N, Haynes K, Berns JS. Use of antiepileptic drugs in patients with kidney disease. Semin Dial 2006; 19:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Depner TA, Gulyassy PF. Plasma protein binding in uremia: extraction and characterization of an inhibitor. Kidney Int 1980; 18:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds F, Ziroyanis PN, Jones NF, Smith SE. Salivary phenytoin concentrations in epilepsy and in chronic renal failure. Lancet 1976; 2:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faridi MM, Aggarwal A. Phenytoin induced vitamin D deficiency presenting as proximal muscle weakness. Indian Pediatr 2010; 47:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee RH, Lyles KW, Colón-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother 2010; 8:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bansal AD, Hill CE, Berns JS. Use of Antiepileptic Drugs in Patients with Chronic Kidney Disease and End Stage Renal Disease. Semin Dial 2015; 28:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porto I, John EG, Heilliczer J. Removal of phenobarbital during continuous cycling peritoneal dialysis in a child. Pharmacotherapy 1997; 17:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kandrotas RJ, Love JM, Gal P, Oles KS. The effect of hemodialysis and hemoperfusion on serum valproic acid concentration. Neurology 1990; 40:1456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kandrotas RJ, Oles KS, Gal P, Love JM. Carbamazepine clearance in hemodialysis and hemoperfusion. DICP 1989; 23:137.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1894 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1571218" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Dialysis-associated seizures in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34548293" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Hypertensive emergency and seizures during haemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8196263" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Dialysis disequilibrium syndrome: current concepts on pathogenesis and prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1777585" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Cardiovascular complications in renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/851303" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Osmolality changes during hemodialysis. Natural history, clinical correlations, and influence of dialysate glucose and intravenous mannitol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22710692" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Dialysis disequilibrium syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18764799" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Dialysis disequilibrium syndrome: a narrative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15318947" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Dialysis Disequilibrium Syndrome: brain death following hemodialysis for metabolic acidosis and acute renal failure--a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21517979" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Low-efficiency acute renal replacement therapy: role in acute kidney injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8188400" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Seizures in dialysis patients treated with recombinant erythropoietin. Review of the literature and guidelines for prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2517327" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Seizures in haemodialysis patients treated with recombinant human erythropoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15579519" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17496739" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Piperacillin/tazobactam-induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12779103" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Neurotoxicity induced by Cefepime in a very old hemodialysis patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10620557" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Successful treatment of normeperidine neurotoxicity by hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1462997" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Neurotoxicity of acyclovir in patients with end-stage renal failure treated with continuous ambulatory peritoneal dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7777108" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Avoiding acyclovir neurotoxicity in patients with chronic renal failure undergoing haemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12748346" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10866333" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : High-efficiency dialysis for carbamazepine overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15644469" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Ertapenem-associated seizures in a peritoneal dialysis patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8793235" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Contrast-induced encephalopathy and seizures in a patient with chronic renal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10676715" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Fatal outcome after ingestion of star fruit (Averrhoa carambola) in uremic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12480969" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Intoxication by star fruit (Averrhoa carambola) in 32 uraemic patients: treatment and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1244532" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The dialysis encephalopathy syndrome. Possible aluminum intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6756130" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Uremic encephalopathies: clinical, biochemical, and experimental features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/851114" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16970741" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Use of antiepileptic drugs in patients with kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7218662" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Plasma protein binding in uremia: extraction and characterization of an inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/73850" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Salivary phenytoin concentrations in epilepsy and in chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20683115" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Phenytoin induced vitamin D deficiency presenting as proximal muscle weakness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20226391" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A review of the effect of anticonvulsant medications on bone mineral density and fracture risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25929593" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Use of Antiepileptic Drugs in Patients with Chronic Kidney Disease and End Stage Renal Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9250568" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Removal of phenobarbital during continuous cycling peritoneal dialysis in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2118241" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The effect of hemodialysis and hemoperfusion on serum valproic acid concentration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2728503" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Carbamazepine clearance in hemodialysis and hemoperfusion.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
